Deficiency of TNF receptors suppresses microglial
activation and alters the susceptibility of brain
regions to MPTP-induced neurotoxicity: role
of TNF-α by Sriram, Krishnan et al.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Public Health Resources Public Health Resources
2006
Deficiency of TNF receptors suppresses microglial
activation and alters the susceptibility of brain
regions to MPTP-induced neurotoxicity: role of
TNF-α
Krishnan Sriram
Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Morgantown, West Virginia
Joanna M. Matheson
Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Morgantown, West Virginia
Stanley A. Benkovic
Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Morgantown, West Virginia
Diane B. Miller
Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Morgantown, West Virginia
Michael I. Luster
Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Morgantown, West Virginia
See next page for additional authors
Follow this and additional works at: http://digitalcommons.unl.edu/publichealthresources
This Article is brought to you for free and open access by the Public Health Resources at DigitalCommons@University of Nebraska - Lincoln. It has
been accepted for inclusion in Public Health Resources by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.
Sriram, Krishnan; Matheson, Joanna M.; Benkovic, Stanley A.; Miller, Diane B.; Luster, Michael I.; and O'Callaghan, James P.,
"Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced
neurotoxicity: role of TNF-α" (2006). Public Health Resources. 458.
http://digitalcommons.unl.edu/publichealthresources/458
Authors
Krishnan Sriram, Joanna M. Matheson, Stanley A. Benkovic, Diane B. Miller, Michael I. Luster, and James P.
O'Callaghan
This article is available at DigitalCommons@University of Nebraska - Lincoln: http://digitalcommons.unl.edu/
publichealthresources/458
The FASEB Journal • Research Communication
Deficiency of TNF receptors suppresses microglial
activation and alters the susceptibility of brain
regions to MPTP-induced neurotoxicity: role
of TNF-1
Krishnan Sriram, Joanna M. Matheson, Stanley A. Benkovic, Diane B. Miller,
Michael I. Luster, and James P. O'Callaghan2
Centers for Disease Control and Prevention, National Institute for Occupational
Safety and Health, Morgantown, West Virginia, USA
ABSTRACT Enhanced expression of tumor necrosis
factor (TNF) -, is associated with the neuropatholog-
ical effects underlying disease-, trauma- and chemically
induced neurodegeneration. Previously, we have shown
that deficiency of TNF receptors protects against
MPTP-induced striatal dopaminergic neurotoxicity,
findings suggestive of a role for TNF- in neurodegen-
eration. Here, we demonstrate that deficiency of TNF
receptors suppresses microglial activation and alters
the susceptibility of brain regions to MPTP. MPTP-
induced expression of microglia-derived factors,
TNF-, MCP-1, and IL-1, preceded the degeneration
of striatal dopaminergic nerve terminals and astroglio-
sis, as assessed by loss of striatal dopamine and TH,
and an increase in striatal GFAP. Pharmacological
neuroprotection with the dopamine reuptake inhibitor,
nomifensine, abolished striatal dopaminergic neuro-
toxicity and associated microglial activation. Similarly,
in mice lacking TNF receptors, microglial activation
was suppressed, findings consistent with a role for
TNF- in striatal MPTP neurotoxicity. In the hippocam-
pus, however, TNF receptor-deficient mice showed exac-
erbated neuronal damage after MPTP, as evidenced by
Fluoro Jade-B staining (to identify degenerating neurons)
and decreased microtubule-associated protein-2 (MAP-2)
immunoreactivity. These effects were not accompanied
by microglial activation, but were associated with in-
creased oxidative stress (nitrosylation of tyrosine resi-
dues). These findings suggest that TNF- exerts a neuro-
trophic/neuroprotective effect in hippocampus. The
marked differences we observed in the regional density,
distribution and/or activity of microglia and microglia-
derived factors may influence the region-specific role for
this cell type. Taken together, our results are indicative of
a region-specific and dual role for TNF- in the brain: a
promoter of neurodegeneration in striatum and a protec-
tor against neurodegeneration in hippocampus.OSriram,
K., Matheson, J. M., Benkovic, S. A., Miller, D. B., Luster,
M. I., O'Callaghan, J. P. Deficiency of TNF receptors
suppresses microglial activation and alters the susceptibil-
ity of brain regions to MPTP-induced neurotoxicity: role
of TNF-. FASEB J. 20, 670–682 (2006)
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proinflammatory cytokines and chemokines (e.g.,
TNF-, IL-1, and MCP-1) have been implicated as
etiological factors in a variety of neurological disease
states including Alzheimer’s disease (1, 2), multiple
sclerosis (3) and Parkinson’s disease (PD) (4–6). Mi-
croglia and astrocytes are thought to be the primary
sources of cytokines and chemokines that play a role in
brain inflammatory responses (7–9). Both of these cell
types exhibit a reactive phenotype in association with
neurodegenerative diseases (10–13) as well as in re-
sponse to neurotoxic insults (14–17). These observa-
tions suggest that conversion of glial cells to their
“reactive” state, and the associated increase in expres-
sion of cytokines and chemokines, may play a role in
neurodegeneration.
TNF- is prominent among proinflammatory cyto-
kines known to be associated with neuropathological
effects underlying several neurodegenerative disorders
(2, 3, 5, 18). TNF- mediates its biological effects via its
receptors, TNFRSF1A (TNFR1; p55) and TNFRSF1B
(TNFR2; p75). Within the central nervous system,
TNF- is expressed predominantly by glial cells, espe-
cially microglia (19, 20). Expression of TNF- in acti-
vated microglia has been reported in the substantia
nigra of patients with PD (21, 22). Consistent with a
role for TNF- in dopaminergic neurodegeneration,
we previously demonstrated that the effects of the
dopaminergic neurotoxin, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), on multiple indices of
damage to striatal dopaminergic nerve terminals, can
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be blocked in mice lacking both TNF receptors
[Tnfrsf1a(/)/Tnfrsf1b(/); TNFR-DKO], but not
in mice lacking the individual receptors (16). Based on
these previous reports and our prior findings of neuro-
protection in TNF receptor-deficient mice, we specu-
lated that activated microglia may be involved in the
early stages of a cascade of events leading to striatal
dopaminergic nerve terminal degeneration and the
accompanying astroglial reaction (16).
The neurotoxicity profiles of various MPTP dosing
models have been established by assessing multiple
indices of dopaminergic neuronal damage and, to a
lesser extent, indices of the accompanying astroglial
response (16, 17, 23–28) and microglial activation.
Given the limited understanding of microglial involve-
ment in MPTP neurotoxicity, in general, and our prior
speculation that microglia-derived TNF- may play an
early role in disease- or toxicant-related dopaminergic
neurodegeneration, the purpose of the present investi-
gation was to examine the microglial response to
dopaminergic nerve terminal damage after administra-
tion of MPTP. To extend our earlier findings, we
examined proinflammatory cytokines and chemokines
in addition to TNF- and we also examined histological
and biochemical markers of microglial activation.
While our intent was to characterize the microglial
reaction in striatum, the only known target of MPTP in
our dosing model (e.g., see Materials and Methods and
ref 17), we examined the hippocampus, a non-target
region for MPTP effects, as a negative control. The
hippocampus was examined because previous reports
suggested that microglia-derived TNF- may play a
neuroprotective role against excitotoxic injury in this
structure (29, 30). Our findings did, indeed, implicate
activated microglia as participants in dopaminergic
neurodegeneration caused by MPTP, but we found that
TNF- plays a neuroprotective role in hippocampus.
These apparent region-selective effects associated with
activated microglia suggest that TNF- and other proin-
flammatory cytokines and chemokines play a dual role
in the brain: cytotoxic to some brain regions and
neurotrophic in others.
MATERIALS AND METHODS
Chemicals and reagents
MPTP-HCl was obtained from Aldrich (Milwaukee, WI, USA).
Nomifensine maleate was purchased from Research Bio-
chemicals, Inc. (Natick, MA, USA). Mouse anti-rat tyrosine
hydroxylase (TH) monoclonal antibody and rabbit anti-rat
TH polyclonal antibody were procured from Calbiochem-
Novabiochem Corporation (San Diego, CA, USA). Horserad-
ish peroxidase conjugated anti-rabbit IgG and ECL immuno-
blotting substrate were purchased from Amersham Biosciences
(Piscataway, NJ, USA). Horseradish peroxidase conjugated
anti-mouse IgG and the fluorogenic peroxidase substrate
Quantablu were purchased from Pierce (Rockford, IL, USA).
Mouse monoclonal antibody to MAP-2 was procured from
Chemicon International (Temecula, CA, USA). Rabbit poly-
clonal antiserum to nitrotyrosine was purchased from Alpha
Diagnostic International (San Antonio, TX, USA). Rabbit
polyclonal antibodies to NFB p50 and p65 subunits were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Rabbit polyclonal antibodies to phospho-NFB p50
(Ser529) and phospho-NFB p65 (Ser276) were obtained
from Abcam, Inc. (Cambridge, MA, USA). Fluoro-Jade B was
a kind gift from Dr. Larry C. Schmued, NCTR/FDA, Jeffer-
son, AR. FITC-conjugated anti-rabbit IgG was purchased from
Vector Laboratories (Burlingame, CA, USA). Biotinylated
GSA B4-isolectin from Griffonia simplicifolia (GSA-IB4) and
ABC kit were obtained from Vector Laboratories. Super-
script™ II RNase H– reverse transcriptase and oligo (dT)12-18
primers were procured from Invitrogen (Carlsbad, CA, USA).
TaqMan Universal PCR master mix, SYBR green PCR master
mix, MicroAmp 96-well plates and optical caps for real-time
PCR analysis were purchased from Applied Biosystems (Fos-
ter City, CA, USA). Nitrocellulose membranes were pur-
chased from Schleicher and Schuell (Keene, NH, USA). All
other chemicals and reagents were of analytical grade and
were purchased from Sigma (St. Louis, MO, USA).
Animals
Male mice aged 4–6 months (28–35 g) were used in all
experiments. Mice carrying homozygous mutant alleles for
both TNF receptors [Tnfrsf1a(/)/Tnfrsf1b(/); TNFR-
DKO] were a kind gift from Dr. Larry Schook, University of
Minnesota and were maintained on a C57BL/6J background
(10 backcross generations). Similarly, appropriate controls
were maintained on a C57BL/6J background. In addition, to
rule out any variations due to strain differences, another set
of the knockouts (B6;129S-Tnfrsf1atm1Imx Tnfrsf1btm1Imx/J),
appropriate strain controls (B6;129SF2/J) and wild-type
C57BL/6J mice were purchased from Jackson Laboratories
(Bar Harbor, ME, USA) and a comparative experiment of the
strains was performed. All the animals were housed in a
temperature (222°C) and humidity-controlled (30–40%)
colony room maintained on a 12 h light:12 h dark cycle.
Animals were allowed ad libitum access to chow and water. All
animal experiments were carried out in accordance with CDC
guidelines for Care and Use of Laboratory Animals. All
procedures were performed under protocols approved by the
Institutional Animal Care and Use Committee of CDC-
NIOSH. The NIOSH animal facility is accredited by the
American Association for Accreditation of Laboratory Animal
Care.
Drug treatment and dissections
Solutions of MPTP, calculated as free-base, were prepared
fresh in 0.9% sodium chloride. Mice were administered a
single dose of MPTP (12.5 mg/kg, s.c., as the base com-
pound) or vehicle (0.9% saline) alone and killed by decapi-
tation at various intervals of time (2–48 h) post-dosing.
Nomifensine (25 mg/kg, s.c.) pretreatment was done 30 min
prior to treatment with MPTP. For the experiments examin-
ing the activation of NFB, mice were killed by focused
microwave irradiation to preserve steady-state protein phos-
phorylation, as described previously (31). The low-dose
MPTP regimen we employed limits the damage and subse-
quent glial response to the striatum by causing degeneration
of a portion of the dopaminergic terminals without affecting
the cell body in the substantia nigra (e.g., 17). By doing so,
our intent was to evaluate very early changes associated with
dopaminergic neurodegeneration in the striatum (e.g., see
refs 32–36). The striatum and hippocampus from both hemi-
spheres were dissected free-hand and used for isolation of
total RNA or analysis of specific proteins. For histopatholog-
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ical assessment, brains were post-perfusion fixed in 4% para-
formaldehyde prior to cutting sections.
RNA isolation, cDNA synthesis, and real-time
PCR amplification
Total RNA from striatum or hippocampus was isolated using
Trizol reagent (Invitrogen) and Phase-lock heavy gel (Ep-
pendorf AG, Hamburg, Germany). The RNA was further
cleaned using RNeasy mini spin column (Qiagen, Valencia,
CA, USA). Total RNA (1 g) was reverse-transcribed to cDNA
using SuperScript™ II RNase H– and oligo (dT)12-18 primers
(Invitrogen) in a 20 L reaction. Real-time PCR analysis of
GAPDH, TNF-, IL-6, MCP-1 (CCL-2), IL-1, MAC-1, and
F4/80 was performed in an ABI PRISM 7700 sequence
detection system (Applied Biosystems) in combination with
TaqMan chemistry. Specific primers and dual labeled inter-
nal fluorogenic (FAM/TAMRA) probe sets (TaqMan Gene
Expression Assays) for these genes were procured from
Applied Biosystems and used according to the manufacturer’s
recommendation. Real-time PCR analysis of TNFR1 and
TNFR2 were performed using SYBR green PCR master mix
and template-specific primers (400 nM) in an ABI PRISM
7700 sequence detection system (Applied Biosystems). Prim-
ers for murine TNFR1 and TNFR2 were procured from
Invitrogen; the sequences are as follows: TNFR1 (X59238,
326bp), 5-TCA AAG AGG AGA AGG CTG G-3 (FP) and
5-CAC CAC AGC ATA CAG AAT CG-3 (RP); TNFR2
(NM_011610, 293bp), TGT AGC ATC CTG GCT ATT CC-3
(FP) and 5-ATG AAG CAG TTC ACC AGT CC-3 (RP). All
PCR amplifications (40 cycles) were performed in a total
volume of 50 L, containing 1 L cDNA, 2.5 L of the
specific Assay on Demand primer/probe mix or 400 nM of
custom primer set and 25 L of either TaqMan Universal
master mix or SYBR green master mix, respectively. Sequence
detection software (version 1.7; Applied Biosystems) results
were exported as tab-delimited text files and imported into
Microsoft Excel for further analysis. Relative quantification of
gene expression was performed using the comparative thresh-
old (CT) method as described by the manufacturer (Applied
Biosystems; User Bulletin 2). Changes in mRNA expression
level were calculated after normalization to GAPDH. The
ratios obtained after normalization are expressed as fold
change over corresponding saline-treated controls.
Tissue preparation for total and specific protein analysis
Tissues for protein analysis were homogenized in 10 volumes
of hot (85–95°C) 1% SDS and stored at –75°C until use. Total
protein was determined by bicinchoninic acid method (37)
using bovine serum albumin as standard.
Tyrosine Hydroxylase (TH) ELISA
TH holoenzyme protein was assessed by a fluorescence-based
ELISA developed in the laboratory. In brief, a mouse mono-
clonal antibody to TH was coated on the wells of Immulon-4
microtiter plates (Thermo Labsystems, Franklin, MA, USA).
The SDS homogenates and standards (homogenates pre-
pared from control mouse striatum) were diluted in phos-
phate-buffered saline (pH 7.4) containing 0.5% Triton-X 100
solution (PBS-T). After blocking nonspecific binding with 5%
non-fat dry milk in PBS, aliquots of the homogenate and
standards were added to the wells and incubated. After
washes, a rabbit polyclonal antibody to TH was added to
“sandwich” the TH protein between the two antibodies. The
amount of sandwich antibody bound to TH was then detected
using a peroxidase-labeled antibody directed against rabbit
IgG. Peroxidase activity was detected using the fluorogenic
substrate Quantablu (Pierce, Rockford, IL, USA) that has
excitation/emission maxima of 325/420 nm (read at 320/
405). The amount of TH in the samples was calculated and
expressed as g TH/mg total protein.
Immunoblot analysis of TH
Changes in TH protein expression were analyzed from im-
munoblots. A linear range for the protein load in the
immunoblot analysis of these proteins was established in our
laboratory earlier (38). Aliquots of brain homogenates (3 g)
were diluted in sample buffer, boiled and loaded on 10%
SDS-polyacrylamide gels (39). Proteins then were electro-
phoretically resolved and transferred to 0.1 m nitrocellulose
membranes (40). After transfer, immunoblot analysis for TH
was performed. All steps were carried out at room tempera-
ture. Briefly, membranes were blocked for 1 h in 5% non-fat
dry milk prepared in PBS-T, washed (115 min; 25 min)
with PBS-T and incubated with antibodies to TH (rabbit
polyclonal, 1:1000) for 2 h. After incubation with primary
antibodies, blots were washed with PBS-T (115 min; 25
min) and subsequently incubated with anti-rabbit IgG-HRP
conjugate (1:2500) for 1 h. Membranes were washed (115
min; 45 min) in PBS-T and the signals detected with a
chemiluminescent substrate, Amersham ECL (Piscataway, NJ,
USA), were captured on X-ray film (Fuji Medical Systems,
Stamford, CT, USA), typically by exposure for 10 s–3 min
depending on the signal intensity.
Histology
For histological evaluation of microglia, animals (saline or
MPTP-treated wild-type mice; n	3 per group) were perfused
transcardially with 100 mL of saline followed by 150 mL of
fresh 4% phosphate-buffered paraformaldehyde. Brains then
were post-fixed for 24 h in 4% paraformaldehyde and frozen
sections (35 m) were cut on a cryostat and stored as
free-floating sections. Microglial staining was performed us-
ing 10 g/mL of biotinylated GSA-IB4 in the presence of 0.1
mM CaCl2 and 0.1 mM MgCl2. The sections were incubated
with GSA-IB4 overnight at 4°C. After washes in PBS (35
min), secondary amplification was performed using the ABC
kit according to the manufacturer’s recommendations. After
washes in PBS (35 min), the sections were incubated with
DAB substrate (0.5 mg/mL) for 5 min. The sections were
then rinsed in PBS, mounted on Colorfrost 
 slides (Fisher
Scientific, Pittsburgh, PA, USA), air-dried overnight, dehy-
drated through a series of graded alcohol, and cover-slipped
with Permount.
For histological analysis of neuronal damage, another set
of animals (saline or MPTP-treated wild-type or TNFR-DKO
mice; n	4 per group) were perfused as above. After post-fix
in 4% paraformaldehyde, the sections were embedded in
paraffin. Sagittal 8 m-thick sections were cut on a microtome
and serial sections were mounted on Superfrost plus slides
(Fisher Scientific). The paraffin embedded sagittal sections
were deparaffinized, rehydrated and processed for antigen
retrieval using an antigen unmasking solution (Vector Labo-
ratories). Serial sections, in quadruplicate, were stained with
hematoxylin and eosin (H&E) for anatomical/histopatholog-
ical evaluation. Similarly, corresponding sections, from each
group were stained with Fluoro-Jade B solution, a marker for
localizing degenerating neurons (41). Sections were succes-
sively rinsed in 80% alcohol containing 1% sodium hydroxide
and 70% alcohol for 2 min, respectively. After washes in
distilled water (32 min), the sections were incubated in a
0.06% solution of potassium permanganate for 10 min and
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washed in distilled water again as above. The sections were
then incubated for 20 min in 0.001% Fluoro-Jade B prepared
in 0.1% glacial acetic acid. After washes in distilled water the
sections were air-dried for 5–10 min prior to mounting in an
anti-fade solution, Vectashield (Vector Laboratories). The
sections were examined under a fluorescence microscope
(Olympus AX70) with a filter cube for FITC (excitation
460–490 nm; emission filter 515 nm; wide band pass). Digital
(.tif) images were captured using Sony 3CCD color video
camera (DXC9000, Sony Electronics Inc., NJ, USA) and
Simple32 software (Compix Inc. Imaging Systems, Cranberry
Township, PA, USA) and documented.
Immunohistochemistry for TH (mouse monoclonal, 1:1000),
nitrotyrosine (rabbit polyclonal, 1:1000) or microtubule associ-
ated protein (MAP) -2 (mouse monoclonal, 1:1000), another
marker for neuronal damage, were performed similarly on
corresponding serial sections. In brief, sections were treated with
10% methanol/hydrogen peroxide solution for 15 min to
quench endogenous peroxidase. The sections were washed
(35 min) in PBS, then permeabilized in a solution containing
1.8% L-lysine, 4% normal horse serum and 0.2% Triton-X-100
in PBS. Primary antibody (1:1000) diluted in a solution contain-
ing PBS and 4% normal horse serum was then added to the
sections and incubated overnight at 4°C. After overnight incu-
bation, sections were washed in PBS (35 min) and incubated
for 2 h at room temperature in FITC-conjugated anti-mouse IgG
(1:500). Sections were then washed (35 min) with PBS and
mounted in Vectashield. Epifluorescence was visualized in a
photomicroscope (Olympus AX70) under blue light (for FITC;
excitation 460–490 nm; emission filter 515 nm; wide band pass).
Digital (.tif) images were captured using Sony 3CCD color video
camera (DXC9000, Sony Electronics Inc., NJ, USA) and Sim-
ple32 software (Compix Inc. Imaging Systems, Cranberry Town-
ship, PA, USA) and documented.
Pathology scoring
Slides were scored for severity of pathological profiles after
Fluoro-Jade B staining using a semiquantitative 4-point rating
scale: 0 	 no pathology; 1 	 mild pathology; 2 	 moderate
pathology; 3 	 severe pathology. Pathology scores were
determined by low magnification microscopy (10) of the
entire hippocampus. Evaluation of pathology was performed
by one author (SAB) and was verified by an independent
observer who was blind with respect to treatment groups
(KS).
Statistical analysis
Statistical analyses of data from biochemical assays were
performed using SigmaStat (version 3.0) statistical software
(Systat Software, Inc., Point Richmond, CA, USA). The test of
significance was performed using one way ANOVA (ANOVA)
followed by Student-Newman-Keuls (SNK) test. Values were
considered statistically significant at 5% level of significance
(P0.05). Graphical representations are mean  se.
Statistical analysis of pathology quantification was per-
formed using JMP (SAS Institute, Cary, NC, USA). Data were
analyzed using a one-way nonparametric Wilcoxon/Kruskal-
Wallis ANOVA, and differences in means were considered
significant when Prob2 values were less than 0.05.
RESULTS
MPTP causes a loss of striatal TH protein that
is attenuated in TNFR-DKO mice
Administration of MPTP to wild-type C57BL/6J mice
causes striatal dopaminergic neurodegeneration and
an attendant astrogliosis, as determined by loss of
striatal dopamine and TH, and an increase in striatal
GFAP (16, 17, 27, 42). Similarly, B6;129S mice admin-
istered MPTP exhibited an identical loss of striatal TH.
This latter experiment was performed to confirm that
no significant differences existed between the two
strains, because the TNFR-DKO mice were originally on
a B6;129S background prior to being outbred and
maintained on a C57BL/6J background, as described
in Materials and Methods. In TNFR-DKO mice, how-
ever, the loss of striatal TH protein was significantly
attenuated compared with the TH protein decreases
seen in wild-type mice (Fig. 1). Within 12 h of MPTP
treatment, striatal TH protein levels decreased by 40–55%
in wild-type C57BL/6J and B.129S mice, as determined by
ELISA (P0.05; Fig. 1A). By 48 h post-dosing, the loss of
TH was nearly 60% (P0.01; Fig. 1A). In contrast, the
maximal decrement of striatal TH protein in TNFR-DKO
mice was only 17%, indicating significant attenuation of
TH loss (Fig. 1A). Since no significant differences were
observed between the two strains, all subsequent experi-
ments were performed using the C57BL/6J strain as
wild-type controls. The choice of this strain was appropri-
ate since the TNF receptor knockouts were maintained
on this background for 10 generations. Immunoblot
analysis of TH revealed similar differences between wild-
type and TNFR-DKO mice, in agreement with the results
from TH ELISA (Fig. 1B). The changes in striatal TH
were verified by immunohistochemical analysis using
coronal brain sections from wild-type and TNFR-DKO
mice treated with saline or MPTP (Fig. 1C). These data,
while confirming and extending the time course of our
previous observation (16), also suggest that microglia-
derived TNF-may play a role in the neurotoxic effects of
MPTP.
MPTP-induced striatal dopaminergic
neurodegeneration elicits microglial activation
While activated microglia are implicated as etiological
factors in several neurodegenerative diseases, their role
in dopaminergic neurodegeneration has not been ex-
amined in great detail. Therefore, we evaluated micro-
glial activation after administration of MPTP. MPTP-
induced microglial activation was confirmed by staining
with isolectin-B4 (Fig. 2). Corresponding brain sections
from saline and 24 h MPTP-treated wild-type mice
stained for isolectin B4 revealed microglial activation in
the striatum after MPTP treatment (Fig. 2). Isolectin B4
staining appeared to be confined to striatum; other
brain areas were not affected (data not shown), consis-
tent with the known targets of MPTP using our dosing
regimen (17, 27). If microglial activation is engendered
by MPTP-induced damage to dopaminergic nerve ter-
minals, then neuroprotection with dopamine reuptake
inhibitors should block the activation of microglia.
Pretreatment with a selective dopamine reuptake inhib-
itor, nomifensine, abolished the striatal microglial acti-
vation elicited by MPTP, as revealed by isolectin-B4
staining (Fig. 2).
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MPTP treatment causes enhanced expression of
microglial markers and microglia-derived cytokines
and chemokines in the striatum
In addition to histological verification of MPTP-in-
duced striatal microglial activation by analysis of isolec-
tin B4 staining, we observed enhanced expression of
several markers known to be associated with activated
microglia in the striatum of wild-type mice. This in-
cluded increased striatal mRNA expression of cytokines
and chemokines typically expressed by microglia, such
as, TNF-, MCP-1, and IL-1 (Fig. 3A–C) and of the
microglial marker F4/80 (Fig. 3D). The expression of
these microglia-associated mRNAs was quantified by
TaqMan real-time PCR analysis. Within 2–4 h of
dosing with MPTP, striatal TNF-, MCP-1, and IL-1
mRNA levels increased by 2.2, 4.3- and 3.7-fold
(P0.05), respectively (Fig. 3A–C). The mRNA levels
increased in a time dependent manner and by 12–24 h
after MPTP, the levels of these mRNAs increased by
nearly 8- to 20-fold (P0.01; Fig. 3A–C). A small
increase (2.5-fold; P0.05) in the mRNA expression of
the microglial cell surface marker, F4/80, was observed
by 12–24 h after MPTP (Fig. 3D). The time course of
striatal F4/80 mRNA expression is consistent with his-
tological evidence for microglial activation reported for
a single subcutaneous dose of MPTP (43).
In the hippocampus, a nontarget region for the
neurotoxic effects of MPTP, no up-regulation of TNF-,
IL-1, or F4/80 mRNAs was observed (Fig. 3E, G, H),
consistent with a lack of damage and, therefore, of
microglial activation in this structure. Nevertheless, a
rapid and large increase in MCP-1 mRNA was observed
in hippocampus that did not persist beyond 4 h post-
dosing (Fig. 3F ). The time course of the increase in
MCP-1 mRNA in hippocampus did not coincide with
the apparent time course for microglial activation seen
with all other microglial markers analyzed in striatum,
including MCP-1. Although an early activation of hip-
pocampal microglia cannot be ruled out based on the
hippocampal MCP-1 mRNA response, the significance
of this increase was not further evaluated in the present
study.
Figure 2. Striatal dopaminergic neurotoxicity due to MPTP is
associated with microglial activation. Wild-type mice were
administered either saline or MPTP (12.5 mg/kg, s.c.) and
24 h later were processed for immunohistochemical analysis
of microglial activation using isolectin B4. Immunostaining
for activated microglia in brain sections from saline or
nomifensine 
 saline-treated animals reveals no staining for
striatal (STR) microglia in these control sections. Similar
staining in MPTP-treated animals reveals intense staining
(dark brown) of activated microglia in the striatum. Nomi-
fensine pretreatment abolishes microglial activation associ-
ated with MPTP neurotoxicity, thus confirming pharmacolog-
ical neuroprotection by nomifensine. Scale bars: A–D) 50 m.
Figure 1. Loss of striatal TH protein due to MPTP is attenuated
in TNFR-DKO mice. Wild-type C57BL/6J (e), wild-type B6.129S
(r), and TNFR-DKO (f) mice were administered either saline
or MPTP (12.5 mg/kg, s.c.) and killed at various intervals of time
(6–48 h). A) Loss of striatal TH protein seen in wild-type
C57BL/6J or B6.129S mice is attenuated in mice lacking both
TNF receptors. Striatal TH protein levels were quantified by a
fluorescence-based ELISA. Graphical representations are
mean  se (n	5 animals per time point) and TH levels are
expressed as g/mg total protein. *Significantly different from
saline-treated controls (P0.01). #Significantly different from
corresponding treatment in wild-type group (P0.05). Newman
Keuls pairwise comparisons were used for post hoc statistical
analysis. B) Immunoblot analysis of striatal TH protein. Repre-
sentative samples (in triplicate) from saline and MPTP (12 h)
-treated groups were used for immunoblot analysis. C) Wild-type
and TNFR-DKO mice (n	4 per group) were administered
either saline or MPTP (12.5 mg/kg, s.c.), killed 48 h after
injection and processed for histopathological analysis. Four sets
of serial coronal sections from each treatment group were
independently stained in each analysis. Immunohistochemical
analysis of striatal (STR) TH was performed to confirm the loss
of striatal TH determined by ELISA and immunoblots. MPTP
treatment caused extensive loss of striatal TH protein. The loss
of striatal TH caused by MPTP was significantly attenuated in
TNFR-DKO mice. Representative photomicrographs from each
experimental group are depicted here. Scale bar 	 140 m.
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Nomifensine pretreatment blocks MPTP-induced
expression of microglial markers and microglia-
derived cytokines and chemokines
It was possible that the enhanced expression of
microglial markers and microglia-associated cyto-
kines and chemokines seen in striatum in response to
MPTP treatment was unrelated to nerve terminal
damage and the subsequent activation of microglia.
Therefore, as we did to confirm the origins of
isolectin-B4 staining (Fig. 2), we administered nomi-
fensine prior to MPTP to block its neurotoxic effects.
This pretreatment completely abolished the induc-
tion of TNF-, MCP-1, IL-1, and F4/80 mRNAs in
the striatum of wild-type mice (Fig. 4A–D), indicating
that the enhanced expression of these microglia-
associated factors occurs in response to striatal dopa-
minergic nerve terminal damage.
MPTP-induced up-regulation of TNF receptors is
region-selective: Increased levels are observed in
striatum but not in hippocampus
Of the microglia-associated cytokines and chemokines
affected by MPTP treatment, TNF- appears to exhibit
the greatest response. A predicted consequence of this
elaboration of TNF- would be modulation of its recep-
tors, TNFR1 and TNFR2. Analysis of the mRNA expres-
sion of these receptors by real-time PCR analysis indi-
cated that TNFR1 and TNFR2 mRNAs were selectively
up-regulated only in the striatum and not in the
hippocampus of wild-type mice (Fig. 5A). Striatal
TNFR1 mRNA expression increased by 2.7-fold
(P0.05) within 6 h of MPTP administration and
continued to increase in a time-dependent manner. By
24 h after MPTP, an 8-fold increase (P0.001) in
TNFR1 mRNA was observed in the striatum. Striatal
TNFR2 mRNA, however, did not significantly increase
until 12 h after MPTP (2-fold, P0.05). Neither TNFR1
nor TNFR2 mRNAs were induced by MPTP in the
hippocampus (Fig. 5A). These effects are consistent
with MPTP-induced expression of microglia-associated
TNF- in striatum but not in hippocampus.
Lack of nuclear factor–kappa B (NFB) activation
after MPTP treatment
Since MPTP treatment caused a rapid increase in the
expression of TNF- and its receptors, we examined
whether MPTP also caused an induction of NFB, the
downstream transcription factor associated with TNF
Figure 3. Striatal dopaminergic neurotoxicity due to MPTP is
associated with up-regulation of microglial markers. Wild-type
mice were administered saline or MPTP (12.5 mg/kg, s.c.)
and killed at various intervals of time (2–24 h). Striatal mRNA
expression of microglial factors, A) TNF-, B) MCP-1, C)
IL-1, and D) F4/80 were measured by TaqMan real-time
PCR analysis. E–H) The mRNA expressions of these factors in
the hippocampus were similarly analyzed. Graphical repre-
sentations are mean  se (n	6 animals per time point; from
2 independent experiments) and are expressed as fold
change over saline-treated controls. *Significantly different
from respective saline-treated controls (P0.05–0.01). New-
man Keuls pairwise comparisons were used for post hoc
statistical analysis.
Figure 4. Striatal microglial activation due to MPTP is blocked
by pharmacological modulation with nomifensine. Wild-type
mice were pretreated with nomifensine (25 mg/kg, s.c.) 30
min prior to administration of either saline or MPTP (12.5
mg/kg, s.c.) and killed 12 h later. A–C) The striatal mRNA
expression of microglia-derived factors, TNF-, MCP-1, IL-1,
and D) the microglial marker, F4/80, were measured by
TaqMan real-time PCR analysis. Graphical representations
are mean  se (n	6 animals per time point; from 2 inde-
pendent experiments) and are expressed as fold change over
saline-treated controls. *Significantly different from respec-
tive saline-treated controls (P0.05–0.01). #Significantly dif-
ferent from MPTP-treated group (P0.001). Newman Keuls
pairwise comparisons were used for post hoc statistical anal-
ysis.
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signaling. Interestingly, MPTP treatment failed to induce
NFB (levels or phosphorylation) in either the striatum
or hippocampus of wild-type and TNFR-DKO mice (Fig.
5B). These findings suggest that NFB-independent
mechanisms may be responsible for striatal dopaminergic
nerve terminal damage caused by MPTP.
MPTP-induced microglial activation in the striatum is
attenuated in TNFR-DKO mice
To further characterize the involvement of microglia in
MPTP neurotoxicity and to evaluate the region-specific
role exhibited by the proinflammatory cytokine,
TNF-, we examined the effects of MPTP in mice
lacking TNF receptors. Specifically, we determined
whether variations in microglial activation between
wild-type and TNFR-DKO mice could underlie the
observed regional differences in response to MPTP. To
achieve this, we analyzed the mRNA expression of
microglia-associated genes TNF-, MCP-1, IL-1 and
F4/80 mRNAs in these two groups of mice (Fig. 6A–D).
By 12 h of MPTP administration, a 4- to 20-fold increase
(P0.05; Fig. 6A–D) in the levels of these mRNAs was
observed in the striatum of wild-type mice, which was
significantly attenuated in TNFR-DKO mice (Fig. 6A–
D), findings consistent with decreased microglial acti-
vation. Since microglial activation has been associated
with increased neurotoxicity, the above observation
appeared to be consistent with striatal neuroprotection
observed in these mice (16). Microglial activation,
however, was not observed in the hippocampus of
wild-type or TNFR-DKO mice (Fig. 6E–H ), findings
consistent with lack of microglial activation and of
MPTP-induced damage in this structure.
Neuronal injury in the hippocampus of MPTP-treated
TNFR-DKO mice
Histopathological analysis of the brains based on H&E
staining revealed no significant differences between
Figure 5. TNF receptors are selectively expressed in the
striatum after MPTP treatment. Wild-type mice were admin-
istered either saline or MPTP (12.5 mg/kg, s.c.) and killed at
various intervals of time (2–24 h). A) Striatal and hippocam-
pal TNFR1 and TNFR2 mRNA expression was measured by
TaqMan real-time PCR analysis. Graphical representations
are mean  se (n	6 animals per time point; from 2 inde-
pendent experiments) and are expressed as fold change over
saline-treated controls. *Significantly different from respec-
tive saline-treated controls (P0.05–0.01). Newman Keuls
pairwise comparisons were used for post hoc statistical anal-
ysis. B) Immunoblot analysis of phosphorylated and unphos-
phorylated forms of NFB (p50 and p65) in striatum and
hippocampus of wild-type or TNFR-DKO mice treated with
MPTP. Representative samples (in triplicate) from saline and
MPTP (48 h) -treated groups were obtained after sacrifice of
mice by focused microwave irradiation to preserve steady-state
protein phosphorylation.
Figure 6. Striatal microglial activation due to MPTP is atten-
uated in mice lacking TNF receptors. Wild-type and TNFR-
DKO mice were administered either saline or MPTP (12.5
mg/kg, s.c.) and killed 12 h later. A–C) The striatal mRNA
expression of microglia-derived factors, TNF-, MCP-1, IL-1,
and D) the microglial marker, F4/80 were measured by
TaqMan real-time PCR analysis. E–H) The mRNA expres-
sions of these factors were similarly measured in the hip-
pocampus. Graphical representations are mean  se (n	6
animals per time point; from 2 independent experiments)
and are expressed as fold change over saline-treated controls.
*Significantly different from respective saline-treated controls
(P0.01). #Significantly different from MPTP-treated group
(P0.05). Newman Keuls pairwise comparisons were used for
post hoc statistical analysis.
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wild-type and TNFR-DKO mice with respect to overall
cytoarchitecture and apparent cellular density (Fig.
7A–C). A limitation of H&E staining, however, is that
significant cellular loss must occur before pathological
changes are observed (e.g., see ref 44). This drawback
can be overcome by employing more sensitive indica-
tors of neuronal damage, such as Fluoro-Jade B staining
(44). Brains of wild-type mice administered MPTP did
not exhibit any significant neuronal perikaryal damage
based on Fluoro-Jade B staining (Fig. 7F–H ). This was
expected given the fact that the neurotoxicity of MPTP
in our dosing model is predominantly restricted to
damage of dopaminergic nerve terminals that do not
stain with Fluoro-Jade B. Surprisingly, however, defi-
ciency of TNF receptors rendered the hippocampus
vulnerable to neuronal damage by MPTP, as evidenced
by Fluoro-Jade B staining of degenerating neurons (Fig.
7F–H ) and follow-up immunostaining of MAP-2 to
detect loss of dendritic processes (Fig. 7D, E). Fluoro-
Jade B staining revealed neuronal degeneration in the
CA3 area (Fig. 7G) and dentate gyrus (Fig. 7H ) of the
hippocampus in TNFR-DKO mice (quantitation of
these data are presented in Fig. 7I ). Similarly, MAP-2
immunostaining revealed significant loss of immunore-
activity in the hippocampus (CA3 region shown here)
of TNFR-DKO mice (Fig. 7C). Thus, neuronal damage
due to MPTP was seen in the hippocampus of TNFR-
DKO mice in the absence of an associated microglial
activation or astrocytic activation (data not shown).
Fluoro-Jade B staining or MAP-2 immunostaining did
not reveal any neuronal loss in the striatum of TNFR-
DKO mice (data not shown). These data suggest that
TNF- plays region-specific roles in the CNS.
Basal levels of microglial markers and microglia-
derived factors are higher in hippocampus
than striatum
To determine the possible basis of the regional differ-
ence in the neurotoxic effects of MPTP seen above, we
analyzed the expression of various microglia-associated
factors in the striatum and hippocampus of wild-type
mice. The mRNA expression of the microglial markers
F4/80 and MAC-1 were significantly higher (2- and
5-fold, respectively; P0.05) in the hippocampus, sug-
gesting that the number of microglia and/or their
activation state varied across brain regions (Fig. 8A).
The mRNA expression of cytokines and chemokines
released from microglia, such as TNF-, MCP-1, and
IL-, exhibited a similar pattern. The basal levels of
mRNA expression of all these microglial factors were
3-fold higher in the hippocampus than in the striatum
(Fig. 8B). Such regional differences in the microglial
number and/or content may determine the role micro-
glia take in influencing the fate of the neurons in that
particular region.
Oxidative damage may underlie MPTP-induced
hippocampal neuronal injury in TNFR-DKO mice
To determine the possible cause for increased vulner-
ability of hippocampal neurons in TNFR-DKO mice to
MPTP, we examined the role of oxidative stress in
mediating the neurotoxic outcome. As basal levels of
microglia are higher in the hippocampus (as evaluated
above) it seemed plausible that this region may be
more vulnerable to oxidative damage, because micro-
glia are known to be initiators as well as mediators of
oxidative stress. Immunohistochemical analysis using
anti-nitrotyrosine antibody revealed that MPTP treat-
ment increased peroxynitrite-mediated oxidative injury
selectively in the hippocampus of TNFR-DKO mice
(Fig. 9). Extensive nitrotyrosine staining was observed
in the CA1, CA3 (shown here; Fig. 9) and dentate gyrus
regions of the hippocampus of MPTP-treated TNFR-
DKO mice. These observations are consistent with the
increased Fluoro-Jade B staining and decreased MAP-2
immunoreactivity (indicating neuronal degeneration)
Figure 7. Lack of TNF receptors renders the hippocampus
susceptible to MPTP-induced neurodegeneration: detection
of increased Fluoro-Jade B staining and decreased MAP-2
immunostaining. Wild-type and TNFR-DKO mice (n	4 per
group) were administered either saline or MPTP (12.5 mg/
kg, s.c.), killed 48 h after injection and processed for his-
topathological analysis. Four sets of serial sagittal sections
from each treatment group were independently stained in
each analysis. A–C) H&E staining revealed no developmental
anomalies in TNFR-DKO mice. (D, E) MAP-2 immunostain-
ing revealed axonal and neurite loss in the hippocampus of
TNFR-DKO mice, treated with MPTP. Extensive loss of MAP-2
immunoreactivity was observed in the CA3 region of the
hippocampus. No loss of MAP-2 immunoreactivity was seen in
wild-type mice treated with MPTP. F–H) Fluoro-Jade B stain-
ing reveals extensive neuronal degeneration in the CA3 and
dentate gyrus (DG) regions of the hippocampus of TNFR-
DKO mice after MPTP treatment. No neurodegeneration was
detected in the hippocampus of wild-type mice. Representa-
tive photomicrographs from each experimental group are
depicted here. I) Quantitation of MPTP-induced degenera-
tion, as detected by Fluoro-Jade B staining, revealed signifi-
cant damage in the hippocampus of TNFR-DKO mice. HIP,
hippocampus; CTX, cortex; CER, cerebellum; CA3, cornu
ammonis 3 field of hippocampus; DG, dentate gyrus. Scale
bar: A–C) 200 m; D, F) 500 m; E, G, H) 33 m.
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seen in the hippocampus of TNFR-DKO mice treated
with MPTP.
DISCUSSION
Microglial activation and the elaboration of microglia-
associated cytokines and chemokines have been linked
to various forms of neurological and neurodegenera-
tive disorders (2, 5, 18). Key among the cytokines
associated with neurodegenerative processes is TNF-,
a proinflammatory cytokine that we previously impli-
cated in the neurodegenerative effects of the dopami-
nergic neurotoxicant, MPTP. Here we have provided
morphological and biochemical evidence for micro-
glial activation in response to the dopaminergic nerve
terminal damage caused by MPTP. We expanded the
repertoire of microglial cytokines and chemokines as-
sociated with MPTP exposure beyond TNF- to include
MCP-1, and IL-1. Because TNFR-DKO mice were
protected against MPTP-induced neurotoxicity, TNF-
and other microglia-derived cytokines and chemokines
may play a role in dopaminergic nerve terminal degen-
eration caused by this toxicant. Nevertheless, our unex-
pected observation that the hippocampus of TNFR-
DKO mice was rendered vulnerable to MPTP-induced
neurotoxicity is indicative of a dual role of TNF- in the
brain: promoter of neurodegeneration in the striatum
and protector against neurodegeneration in the hip-
pocampus. A schematic illustration of the region-spe-
cific role for microglia-derived TNF- in brain injury/
neurotoxicity is represented in Fig. 10.
The low-dose MPTP regimen used in this study was
established in our laboratory to cause selective degen-
eration of striatal dopaminergic nerve terminals and to
elicit a glial response without affecting dopaminergic
cell bodies in the substantia nigra (16, 17, 27, 42).
While we have extensively documented that the astro-
glial response to MPTP in our model is linked to
dopaminergic nerve terminal damage and restricted to
the striatum (e.g., see ref 17), until now, we had no
evidence for microglial activation in response to MPTP
using our regimen. As with the astroglial response to
MPTP (17, 27), we can now link the activation of
microglia to dopaminergic nerve terminal damage.
This view is based on the fact that protection of
dopaminergic nerve terminals against MPTP in the
striatum with a selective dopamine reuptake inhibitor,
nomifensine, blocked microglial activation, the expres-
sion of microglia-associated cytokines and chemokines,
Figure 8. Regional differences in number and expression of
microglial markers and microglia-derived factor. Wild-type
mice were administered saline and killed 12 h later. A) mRNA
expression of the microglial markers, F4/80 and MAC-1 in
striatum (e) and hippocampus (f) reveals increased basal
levels of expression in hippocampus. B) mRNA expression of
the microglia-derived factors, TNF-, MCP-1, and IL-1 in
striatum (e) and hippocampus (f) reveal a similar increase
in basal levels of expression in hippocampus. The mRNA
expression of these markers was measured by TaqMan
real-time PCR analysis. Graphical representations are mean
se (n	3 animals) and are expressed as fold change over
corresponding levels in striatum. *Significantly different from
corresponding level in striatum (P0.05–0.01). Newman
Keuls pairwise comparisons were used for post hoc statistical
analysis.
Figure 9. Lack of TNF receptors renders the hippocampus
susceptible to MPTP-mediated oxidative injury: detection of
increased nitrotyrosine staining. Wild-type and TNFR-DKO
mice (n	4 per group) were administered either saline or
MPTP (12.5 mg/kg, s.c.), killed 48 h later and processed for
histopathological analysis. Four sets of serial sagittal sections
from each treatment group were independently stained in
each analysis. Immunohistochemical analysis of nitrotyrosine
in saline or MPTP-treated wild-type mice or in saline-treated
TNFR-DKO mice did not reveal any staining in the hippocam-
pus. However, in MPTP-treated TNFR-DKO mice extensive
nitrotyrosine staining was observed in the CA3 region. Rep-
resentative photomicrographs from each experimental group
are depicted. Scale bar 	 140 m.
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and the expression of a microglial selective cell-surface
marker. The time course for these microglial-associated
responses in striatum precedes the time course for
astroglial activation in our model (17), findings consis-
tent with a microglial response to neural injury that
precedes astroglial activation in a variety of other
neural damage models (45–47).
While extremely high doses of MPTP, or co-treat-
ments that potentiate its toxicity, have been shown to
cause moderate damage to targets other than the
nigrostriatal dopaminergic pathway (48–52), we find
damage to be restricted to the neostriatum with our
dosing regimen (e.g., see ref 17). Thus, we did not
expect to find evidence of a microglial reaction in
hippocampus after MPTP. The lack of an effect of
MPTP on TNF-, IL-1, F4/80, TNFR1 and TNFR2
mRNA expression in the hippocampus is consistent
with this expectation. The early and transient rise in
hippocampal MCP-1 mRNA, a chemokine known to be
associated with hippocampal microglial activation due
to chemically induced neurodegeneration (53), could
be viewed as evidence for an early microglial reaction to
MPTP-induced damage to this structure. Although we
cannot speculate as to the significance of the rise in
hippocampal MCP-1 mRNA due to MPTP, it is unlikely
to be due to microglial activation. This argument is
supported by the fact that lectin staining did not reveal
morphological evidence for microglial activation in
hippocampus after MPTP and the time course for the
increase and decline of MCP-1 mRNA was earlier than
the time course for morphological evidence for micro-
glial activation seen in striatum. Moreover, microglial
activation usually is accompanied by astrogliosis, which
was not observed in hippocampus with our MPTP
dosing regimen (e.g., see ref 17), nor was there evi-
dence for neuronal degeneration in wild type mice as
assessed by Fluoro-Jade staining or MAP-2 immunohis-
tochemistry.
In TNFR-DKO mice we observed markedly attenu-
ated MPTP-induced striatal dopaminergic neurotoxic-
ity (16; also see Fig. 1). These data were suggestive of a
detrimental role of microglia, as a source for TNF-, in
the observed neurotoxic effects of MPTP. However,
there are contrasting reports on the involvement of
TNF receptors in dopaminergic neurotoxicity, many of
which are modeled on multiple dose regimens of
MPTP (54, 55). Rousselet et al (54). failed to observe
neuroprotection of nigral dopaminergic neurons in
TNF receptor deficient mice after an acute dosing
regimen of MPTP. Leng et al. (55) using a chronic
MPTP regimen also failed to observe neuroprotection.
Nevertheless, an earlier study from the same group
(56) shows that deficiency of the Tnf- gene decreases
the loss of dopaminergic markers in the striatum but
not in the nigra. Dose and dosing regimens of MPTP
seem likely to have affected the outcome of examina-
tions of the role of TNF- in nigral, striatal or nigro-
striatal damage caused by MPTP.
The extensive evidence obtained in the present study
that document a striatal-localized elaboration of micro-
glia-derived factors, in addition to TNF-, is consistent
with a role for microglial activation in association with
MPTP-induced neurotoxicity. The diminished expres-
sion of microglial markers in the striatum of TNFR-
DKO mice after MPTP argues for a contributory role
for microglia in the observed dopaminergic neurotox-
icity. These arguments notwithstanding, the role of
microglia in the neurotoxicity of MPTP remains quite
complex. For example, minocycline, a tetracycline de-
rivative with anti-inflammatory properties distinct from
its antimicrobial effects, has been shown to be neuro-
protective against dopaminergic neurotoxicity caused
by MPTP (57, 58). In contrast, other investigators have
demonstrated that minocycline treatment worsened or
exacerbated MPTP-induced injury (59). We recently
observed (60) that minocycline did not afford neuro-
protection against the neurotoxic effects of MPTP and
methamphetamine in striatum, despite suppression of
several markers of microglial activation in striatum. We
attribute these results to the failure of minocycline to
completely suppress TNF- expression and signaling.
Thus, in aggregate, we think the data suggest that
microglia, in general, and TNF-, in particular, are
crucial players in striatal dopaminergic neurotoxicity
caused by MPTP. Nevertheless, we note that microglia
cannot serve as the primary target for initiation of
neurotoxicity, given that pharmacological protection of
dopaminergic nerve terminals with nomifensine blocks
microglial activation and the production of microglia-
associated factors. In addition, we cannot rule out the
remote possibility that the apparent adverse effects of
TNF- and, potentially, of other proinflammatory cyto-
Figure 10. Schematic diagram depicting a dual role for TNF-
in brain. In the striatum, MPTP treatment results in activation
of microglia and elaboration of microglia-derived proinflam-
matory cytokines, such as TNF-. TNF- triggers degenera-
tion of the dopaminergic nerve terminals by signaling
through its receptors localized on the dopaminergic neurons.
Deficiency of both the TNF receptors results in attenuation of
microglial activation and as a consequence the neurotoxicity.
However, the lack of TNF receptors rendered the hippocam-
pus vulnerable to MPTP-induced neuronal degeneration.
Thus TNF- plays a dual role in brain: neurotoxic in the
striatum and neuroprotective in the hippocampus.
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kines and chemokines, may not emanate from a micro-
glial source after administration of MPTP.
The data obtained in the striatum of TNFR-DKO mice
treated with MPTP demonstrated a neurotoxic role for
TNF-. Thus, it was quite unexpected to find evidence of
neuronal damage in hippocampus of TNFR-DKO mice
treated with MPTP, observations based on two indepen-
dent measures of neuronal damage, Fluoro-Jade B stain-
ing and MAP-2 immunohistochemistry. Equally notable
was the fact that microglial and astroglial activation,
typical responses to neural injury, were not observed in
hippocampus of TNFR-DKO mice after MPTP. With
respect to TNF- these observations are indicative of a
neuroprotective role of this cytokine in hippocampus but
a neurodegenerative role in the striatum. More generally,
these observations suggest that activation of microglia
(and perhaps astroglia as well) in hippocampus is neuro-
protective, while microglial activation in striatum facili-
tates neurodegeneration. These observations are not with-
out precedent. Hippocampal injury has been shown to be
exacerbated in TNF-deficient mice (29) and inhibition of
TNF- in the striatum and hippocampus has been shown
to be neurotoxic and neuroprotective to these structures,
respectively (61). None of these observations rule out the
possibility that physiological levels of hippocampal TNF-
can be neurotrophic, whereas specific pathological con-
ditions resulting in an increase in hippocampal TNF-
could play a role in neurodegenerative responses in this
structure, as observed for striatum after MPTP.
The regional differences in the apparent role of TNF-
in MPTP-induced neurotoxicity are indicative of a dual
nature for TNF signaling in the brain. One of the impli-
cations of these findings is that the vulnerability/suscep-
tibility of various brain regions or neuronal cell types
could be attributed to differences in number and func-
tion of microglia across brain regions, including the
repertoire of cytokines and chemokines elicited from
activated microglia and the signaling pathways activated
by microglial-derived cytokines or chemokines, such as
TNF-. Our analysis of the mRNA expression of select
microglial markers revealed marked differences between
striatum and hippocampus. Specifically, the microglial
content in hippocampus was found to be significantly
greater than that of striatum, as determined by the basal
levels of F4/80 and MAC-1 mRNA. Similarly, the basal
levels of TNF-, MCP-1, and IL-1mRNA expression were
significantly higher in the hippocampus than the stria-
tum. Our findings are in accordance with earlier studies
that reported differences in regional microglial content
(62, 63) and are consistent with the regional differences
we observed in the levels of the astroglial marker GFAP
(64). Such variations in their distribution and content
raise the possibility that regional differences exist in the
way that microglia interact/cross-talk with their immedi-
ate neuro-astroglial microenvironment, as well as in the
way they respond to external stimuli. Although basal levels
of TNF- are not necessarily indicative of a neuroprotec-
tive vs. a neurotoxic role of this cytokine, both of which
have been reported (65–67), differences in the levels and
activational state of the down-stream effectors of this
mediator may serve to confer differences in its functional
roles. In this regard, earlier studies have indicated that
TNF--mediated induction of nuclear factor kappa B
(NF-B) is associated with neuronal survival (68–70). On
the other hand, the inability of TNF- to induce NF-B
has been shown to be associated with increased neurotox-
icity (71). Thus, one possible reason for the differential
role exhibited by TNF- could be attributed to the differ-
ences in the expression of NF-B among various brain
regions. Indeed, such differences in the expression of
NF-B have been known to occur in the CNS (61, 72).
After our MPTP dosing regimen in wild-type and TNFR-
DKO mice, we were unable to detect activation of NF-B
in the striatum despite the observed increases in TNF-.
This observation is consistent with previous findings for
MPTP (73) and suggests that lack of NF-B activation may
result in increased neurotoxicity (71); thereby confirming
that TNF- may elicit a neurotoxic response in the stria-
tum. In contrast, activation of NF-B by TNF- in the
hippocampus has been shown to be neuroprotective after
neurotoxic insult (74). Thus, regional differences in the
expression of TNF- and in the signaling pathways that it
activates, including downstream effectors such as NFB,
may determine the neurotoxic or neurotrophic outcome
in that particular brain region.
Oxidative stress due to production of reactive oxygen
species such as superoxide and hydroxyl radicals, or due
to reactive nitrogen species such as peroxynitrite, has
been implicated in a variety of neurological diseases states.
These include PD (75, 76) as well as experimental models
of dopaminergic neurotoxicity (77–79). In the present
study, we have demonstrated that increased nitrotyrosine
formation, an index of peroxynitrite-mediated oxidative
injury, is associated with the degeneration of hippocam-
pal neurons of TNFR-DKO mice to MPTP. Thus, consis-
tent with above observations that TNF- plays a neurotro-
phic role in the hippocampus, the lack of TNF signaling
due to deficiency of its receptors rendered the hippocam-
pus more susceptible to oxidative injury.
Taken together, our results are suggestive of a region-
specific and dual role for microglia-derived TNF- in the
brain. One implication of these observations is that anti-
TNF therapy directed against certain auto-immune and
inflammatory disorders may have unexpected and nega-
tive consequences on the nervous system. Moreover, there
is no assurance that such concerns should be limited to
effects on nervous tissue. Finally, from a drug discovery
and therapeutic intervention point of view, our findings
suggest the need for comprehensive screening of po-
tential drug candidates across all brain regions and to
demonstrate caution in extrapolating the results of
preliminary/preclinical anti-TNF studies into clinical
practice.
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